Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.

Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock

CRISPR/Cas9 technology allows for precise editing of DNA, potentially treating human diseases by replacing entire genes. CRISPR Therapeutics has developed the first FDA-approved ex vivo CRISPR/Cas9 therapy, Casgevy, for sickle cell disease and transfusion-dependent beta-thalassemia. The market seems pessimistic about the commercialization of these therapies, but if successful, CRISPR Therapeutics could generate significant shareholder value, perhaps nearly equal to the Enterprise Value of the company.

Invest In A Revolutionary Gene Therapy With CRISPR Therapeutics

Despite recent FDA approvals for its groundbreaking gene editing technology, CRISPR Therapeutics' stock has experienced a decline in value. The company's pipeline of treatments for various diseases presents a significant opportunity for future growth and market expansion. CRISPR Therapeutics has managed financial risks through partnerships and has enough cash on hand to fund operations for at least 24 months.

Crispr Therapeutics: Now Is The Time To Buy

ZUG, Switzerland and BOSTON, April 22, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced an oral presentation highlighting the Company's lipid nanoparticle (LNP) approach for ocular editing will be presented at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.

CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

Crispr Therapeutics AG (NASDAQ:CRSP) is 2.8% lower at $56.35 this afternoon, continuing a pullback from a Feb. 22, more than two-year high of $91.10.

Bullish Trendline Has Never Failed Crispr Therapeutics Stock

Is Trending Stock CRISPR Therapeutics AG (CRSP) a Buy Now?

Eli Lilly

Viking Therapeutics

CRISPR Therapeutics has significant upside potential. Eli Lilly could become an even bigger healthcare giant.

3 Magnificent Stocks That Could Double or More by 2030

AbbVie

Johnson & Johnson

Biotech stocks were among the worst performers in 2023. And so far in 2024, investors are still waiting on the recovery rally.

Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024

CRISPR Therapeutics AG (NASDAQ:CRSP ) Annual Needham Virtual Healthcare Conference Call April 10, 2024 11:45 AM ET Company Participants Samarth Kulkarni - Chief Executive Officer and Chairman Conference Call Participants Gil Blum - Needham & Company Gil Blum Good morning, everyone, and thank you for joining us on the Third Day of the Needham Healthcare Conference. My name is Gil Blum and I am a Senior Biotech Analyst with a focus on immune oncology.

CRISPR Therapeutics AG (CRSP) Annual Needham Virtual Healthcare Conference - (Transcript)

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $65.19, marking a +1.72% move from the previous day.

CRISPR Therapeutics AG (CRSP) Exceeds Market Returns: Some Facts to Consider

CRISPR Therapeutics' newly approved product could turn out to be very lucrative. Viking Therapeutics' leading candidate is rightfully grabbing plenty of attention.

Better Buy: CRISPR Therapeutics Vs. Viking Therapeutics

Iovance Biotherapeutics

Both of these companies recently won regulatory approval for their first products. Both Iovance Biotherapeutics and CRISPR Therapeutics have developed game-changing treatment technologies.

Better Growth Biotech Buy: Iovance Biotherapeutics vs CRISPR Therapeutics

ZUG, Switzerland and BOSTON, April 03, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024, at 11:45 a.m. ET.

CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference

ZUG, Switzerland and BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.

CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

Vertex Pharmaceuticals

The sky is the limit for CRISPR Therapeutics. Eli Lilly is a growth machine that will not stop anytime soon.

3 Unstoppable Stocks to Buy Hand Over Fist in April

CRISPR Therapeutics has a diverse pipeline of gene therapies and strategic partnerships, positioning it at the forefront of life science innovation. The approval of CASGEVY, the first CRISPR-based medicine, for transfusion-dependent β-thalassemia and sickle cell disease, signifies a significant milestone for the company. The company has upcoming catalysts, including updates on CASGEVY, the CTX112 program, CTX131, CTX211, CTX310, CTX320, and undisclosed targets, which could validate its technology and drive value creation.

Crispr Therapeutics: Upcoming Catalysts May Validate The Bull Thesis And Force A Change In Plans

Crispr stock is down for the fifth straight week as the top Cathie Wood's holding struggles amid dim expectations for its gene-editing drug.

Crispr Stock, A Cathie Wood Holding, Dives For The Fifth Straight Week — Here's Why

Moderna

Bio-Techne

Last year was a tough one for biotech stocks. The Securities and Exchange Commission reported 41 bankruptcies following the Fed's interest rate hiking cycle, making it difficult to finance debt.

3 Biotech Stocks That Could Be Multibaggers in the Making: March Edition

Medtronic

Pfizer

Investing in a variety of healthcare players could add a lot to your portfolio -- from dividends to growth. This offers you an opportunity to diversify and potentially score a big win over time.

3 No-Brainer Healthcare Stocks to Buy Right Now for Less Than $1,000

Regulatory approvals for Crispr Therapeutics' CASGEVY program are increasing, expanding the potential market for the treatment. Government support, including public funds, is likely to be available for CASGEVY in approved countries. Private insurers are showing interest in covering CASGEVY, providing further support for its commercial launch.

Crispr Therapeutics: CASGEVY Commercial Launch Is Taking Shape

CRISPR Therapeutics AG (CRSP) reachead $71.08 at the closing of the latest trading day, reflecting a -0.74% change compared to its last close.

CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Axsome Therapeutics

Many investors appear to be underestimating Axsome Therapeutics. CRISPR Therapeutics has tremendous long-term prospects.

Buying These Dirt-Cheap Stocks Could Be a Brilliant Move

Novo Nordisk

Biopharma stocks have been among the most popular and well-performing stocks this year. With recent trends in weight loss drugs and clinical advancements in treating illnesses, this market is set for significant advances this year.

3 Biopharma Stocks Predicted to Soar in Q2 2024

CRISPR Therapeutics received important regulatory approvals last year. The company could make plenty of money on its lone marketed product.

Is It Too Late to Buy CRISPR Therapeutics Stock?

Amazon

AeroVironment

Even with the wider market rebound, Cathie Wood hasn't quite recaptured her initial investment allure. Her flagship fund, the ARK Innovation ETF (NYSEARCA: ARKK ), remains a full two-thirds below its 2021 highs.

News for CRISPR Therapeutics Stock (CRSP)